Deciphering the molecular & cellular basis of Low-Grade Glioma

破译分子

• 批准号: 478958
• 负责人: Schramek Daniel
• 金额: $ 76.91万
• 依托单位: Sinai Health System (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-03-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478958&lang=en
• 关键词: Crispr-A Screening; In Vivo Crispr Screening; Low Grade Glioma; Singe Cell Transcriptomics; Crispr-A Screening; In Vivo Crispr Screening; Low Grade Glioma; Singe Cell Transcriptomics

Low-grade glioma (LGG) are brain tumors diagnosed in people between 30-45 years of age. At first, they are relatively benign (not harmful) and tend to grow unrecognized over decades to a size that causes headaches and seizures. Unfortunately, almost all l

低度神经胶质瘤（LGG）是30-45岁的患者诊断出的脑肿瘤。起初，它们是相对良性的（不有害的），并且几十年来倾向于成长，从而导致头痛和癫痫发作的大小。不幸的是，几乎所有L